世界の強皮症治療薬市場規模・現状・予測2021-2027

【英語タイトル】Global Scleroderma Drug Market Size, Status and Forecast 2021-2027

QYResearchが出版した調査資料(QY21APR5135)・商品コード:QY21APR5135
・発行会社(調査会社):QYResearch
・発行日:2021年4月(※2024年版があります。お問い合わせください)
・ページ数:96
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査資料では、強皮症治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(抗炎症剤、免疫抑制剤、抗線維剤)、用途別市場規模(病院薬局、小売薬局、オンライン薬局)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・強皮症治療薬の市場動向
・企業の競争状況、市場シェア
・強皮症治療薬の種類別市場規模(抗炎症剤、免疫抑制剤、抗線維剤)
・強皮症治療薬の用途別市場規模(病院薬局、小売薬局、オンライン薬局)
・強皮症治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・強皮症治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・強皮症治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・強皮症治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・強皮症治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Cumberland Pharmaceuticals、Gilead Sciences、Pfizer、Sanofi、Boehringer Ingelheim、Corbus Pharmaceuticals、Actelion Pharmaceuticals、Bayer、Cytori Therapeutics)
・結論
【レポートの概要】

Scleroderma is a umbrella term for a group of autoimmune diseases resulting in changes in blood vessels, skin, muscles, and other organs. The symptoms of Scleroderma include thickened and stiff skin, lethargy, and poor blood flow to extremities of the limbs such as fingers and toes on exposure to cold. Scleroderma can also result in deposition of calcium deposits, Raynaud’s syndrome, and esophageal problems.

Market Analysis and Insights: Global Scleroderma Drug Market
The global Scleroderma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Scleroderma Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Scleroderma Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Scleroderma Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Scleroderma Drug market.

Global Scleroderma Drug Scope and Market Size
Scleroderma Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Scleroderma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Anti-inflammatory Agents
Immunosuppressive Agents
Anti-fibrotic Agents

Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Cumberland Pharmaceuticals
Gilead Sciences
Pfizer
Sanofi
Boehringer Ingelheim
Corbus Pharmaceuticals
Actelion Pharmaceuticals
Bayer
Cytori Therapeutics

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Scleroderma Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Anti-inflammatory Agents
1.2.3 Immunosuppressive Agents
1.2.4 Anti-fibrotic Agents
1.3 Market by Application
1.3.1 Global Scleroderma Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Scleroderma Drug Market Perspective (2016-2027)
2.2 Scleroderma Drug Growth Trends by Regions
2.2.1 Scleroderma Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Scleroderma Drug Historic Market Share by Regions (2016-2021)
2.2.3 Scleroderma Drug Forecasted Market Size by Regions (2022-2027)
2.3 Scleroderma Drug Industry Dynamic
2.3.1 Scleroderma Drug Market Trends
2.3.2 Scleroderma Drug Market Drivers
2.3.3 Scleroderma Drug Market Challenges
2.3.4 Scleroderma Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Scleroderma Drug Players by Revenue
3.1.1 Global Top Scleroderma Drug Players by Revenue (2016-2021)
3.1.2 Global Scleroderma Drug Revenue Market Share by Players (2016-2021)
3.2 Global Scleroderma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Scleroderma Drug Revenue
3.4 Global Scleroderma Drug Market Concentration Ratio
3.4.1 Global Scleroderma Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Scleroderma Drug Revenue in 2020
3.5 Scleroderma Drug Key Players Head office and Area Served
3.6 Key Players Scleroderma Drug Product Solution and Service
3.7 Date of Enter into Scleroderma Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Scleroderma Drug Breakdown Data by Type
4.1 Global Scleroderma Drug Historic Market Size by Type (2016-2021)
4.2 Global Scleroderma Drug Forecasted Market Size by Type (2022-2027)

5 Scleroderma Drug Breakdown Data by Application
5.1 Global Scleroderma Drug Historic Market Size by Application (2016-2021)
5.2 Global Scleroderma Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Scleroderma Drug Market Size (2016-2027)
6.2 North America Scleroderma Drug Market Size by Type
6.2.1 North America Scleroderma Drug Market Size by Type (2016-2021)
6.2.2 North America Scleroderma Drug Market Size by Type (2022-2027)
6.2.3 North America Scleroderma Drug Market Size by Type (2016-2027)
6.3 North America Scleroderma Drug Market Size by Application
6.3.1 North America Scleroderma Drug Market Size by Application (2016-2021)
6.3.2 North America Scleroderma Drug Market Size by Application (2022-2027)
6.3.3 North America Scleroderma Drug Market Size by Application (2016-2027)
6.4 North America Scleroderma Drug Market Size by Country
6.4.1 North America Scleroderma Drug Market Size by Country (2016-2021)
6.4.2 North America Scleroderma Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Scleroderma Drug Market Size (2016-2027)
7.2 Europe Scleroderma Drug Market Size by Type
7.2.1 Europe Scleroderma Drug Market Size by Type (2016-2021)
7.2.2 Europe Scleroderma Drug Market Size by Type (2022-2027)
7.2.3 Europe Scleroderma Drug Market Size by Type (2016-2027)
7.3 Europe Scleroderma Drug Market Size by Application
7.3.1 Europe Scleroderma Drug Market Size by Application (2016-2021)
7.3.2 Europe Scleroderma Drug Market Size by Application (2022-2027)
7.3.3 Europe Scleroderma Drug Market Size by Application (2016-2027)
7.4 Europe Scleroderma Drug Market Size by Country
7.4.1 Europe Scleroderma Drug Market Size by Country (2016-2021)
7.4.2 Europe Scleroderma Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Scleroderma Drug Market Size (2016-2027)
8.2 Asia-Pacific Scleroderma Drug Market Size by Type
8.2.1 Asia-Pacific Scleroderma Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Scleroderma Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Scleroderma Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Scleroderma Drug Market Size by Application
8.3.1 Asia-Pacific Scleroderma Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Scleroderma Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Scleroderma Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Scleroderma Drug Market Size by Region
8.4.1 Asia-Pacific Scleroderma Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Scleroderma Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Scleroderma Drug Market Size (2016-2027)
9.2 Latin America Scleroderma Drug Market Size by Type
9.2.1 Latin America Scleroderma Drug Market Size by Type (2016-2021)
9.2.2 Latin America Scleroderma Drug Market Size by Type (2022-2027)
9.2.3 Latin America Scleroderma Drug Market Size by Type (2016-2027)
9.3 Latin America Scleroderma Drug Market Size by Application
9.3.1 Latin America Scleroderma Drug Market Size by Application (2016-2021)
9.3.2 Latin America Scleroderma Drug Market Size by Application (2022-2027)
9.3.3 Latin America Scleroderma Drug Market Size by Application (2016-2027)
9.4 Latin America Scleroderma Drug Market Size by Country
9.4.1 Latin America Scleroderma Drug Market Size by Country (2016-2021)
9.4.2 Latin America Scleroderma Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Scleroderma Drug Market Size (2016-2027)
10.2 Middle East & Africa Scleroderma Drug Market Size by Type
10.2.1 Middle East & Africa Scleroderma Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Scleroderma Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Scleroderma Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Scleroderma Drug Market Size by Application
10.3.1 Middle East & Africa Scleroderma Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Scleroderma Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Scleroderma Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Scleroderma Drug Market Size by Country
10.4.1 Middle East & Africa Scleroderma Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Scleroderma Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Cumberland Pharmaceuticals
11.1.1 Cumberland Pharmaceuticals Company Details
11.1.2 Cumberland Pharmaceuticals Business Overview
11.1.3 Cumberland Pharmaceuticals Scleroderma Drug Introduction
11.1.4 Cumberland Pharmaceuticals Revenue in Scleroderma Drug Business (2016-2021)
11.1.5 Cumberland Pharmaceuticals Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Scleroderma Drug Introduction
11.2.4 Gilead Sciences Revenue in Scleroderma Drug Business (2016-2021)
11.2.5 Gilead Sciences Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Scleroderma Drug Introduction
11.3.4 Pfizer Revenue in Scleroderma Drug Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Scleroderma Drug Introduction
11.4.4 Sanofi Revenue in Scleroderma Drug Business (2016-2021)
11.4.5 Sanofi Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Scleroderma Drug Introduction
11.5.4 Boehringer Ingelheim Revenue in Scleroderma Drug Business (2016-2021)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Corbus Pharmaceuticals
11.6.1 Corbus Pharmaceuticals Company Details
11.6.2 Corbus Pharmaceuticals Business Overview
11.6.3 Corbus Pharmaceuticals Scleroderma Drug Introduction
11.6.4 Corbus Pharmaceuticals Revenue in Scleroderma Drug Business (2016-2021)
11.6.5 Corbus Pharmaceuticals Recent Development
11.7 Actelion Pharmaceuticals
11.7.1 Actelion Pharmaceuticals Company Details
11.7.2 Actelion Pharmaceuticals Business Overview
11.7.3 Actelion Pharmaceuticals Scleroderma Drug Introduction
11.7.4 Actelion Pharmaceuticals Revenue in Scleroderma Drug Business (2016-2021)
11.7.5 Actelion Pharmaceuticals Recent Development
11.8 Bayer
11.8.1 Bayer Company Details
11.8.2 Bayer Business Overview
11.8.3 Bayer Scleroderma Drug Introduction
11.8.4 Bayer Revenue in Scleroderma Drug Business (2016-2021)
11.8.5 Bayer Recent Development
11.9 Cytori Therapeutics
11.9.1 Cytori Therapeutics Company Details
11.9.2 Cytori Therapeutics Business Overview
11.9.3 Cytori Therapeutics Scleroderma Drug Introduction
11.9.4 Cytori Therapeutics Revenue in Scleroderma Drug Business (2016-2021)
11.9.5 Cytori Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Scleroderma Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Anti-inflammatory Agents
Table 3. Key Players of Immunosuppressive Agents
Table 4. Key Players of Anti-fibrotic Agents
Table 5. Global Scleroderma Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Scleroderma Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Scleroderma Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Scleroderma Drug Market Share by Regions (2016-2021)
Table 9. Global Scleroderma Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Scleroderma Drug Market Share by Regions (2022-2027)
Table 11. Scleroderma Drug Market Trends
Table 12. Scleroderma Drug Market Drivers
Table 13. Scleroderma Drug Market Challenges
Table 14. Scleroderma Drug Market Restraints
Table 15. Global Scleroderma Drug Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Scleroderma Drug Market Share by Players (2016-2021)
Table 17. Global Top Scleroderma Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Drug as of 2020)
Table 18. Ranking of Global Top Scleroderma Drug Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Scleroderma Drug Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Scleroderma Drug Product Solution and Service
Table 22. Date of Enter into Scleroderma Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Scleroderma Drug Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Scleroderma Drug Revenue Market Share by Type (2016-2021)
Table 26. Global Scleroderma Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Scleroderma Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Scleroderma Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Scleroderma Drug Revenue Market Share by Application (2016-2021)
Table 30. Global Scleroderma Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Scleroderma Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Scleroderma Drug Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Scleroderma Drug Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Scleroderma Drug Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Scleroderma Drug Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Scleroderma Drug Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Scleroderma Drug Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Scleroderma Drug Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Scleroderma Drug Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Scleroderma Drug Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Scleroderma Drug Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Scleroderma Drug Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Scleroderma Drug Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Scleroderma Drug Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Scleroderma Drug Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Scleroderma Drug Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Scleroderma Drug Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Scleroderma Drug Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Scleroderma Drug Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Scleroderma Drug Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Scleroderma Drug Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Scleroderma Drug Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Scleroderma Drug Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Scleroderma Drug Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Scleroderma Drug Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Scleroderma Drug Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Scleroderma Drug Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Scleroderma Drug Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Scleroderma Drug Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Scleroderma Drug Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Scleroderma Drug Market Size by Country (2022-2027) & (US$ Million)
Table 62. Cumberland Pharmaceuticals Company Details
Table 63. Cumberland Pharmaceuticals Business Overview
Table 64. Cumberland Pharmaceuticals Scleroderma Drug Product
Table 65. Cumberland Pharmaceuticals Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 66. Cumberland Pharmaceuticals Recent Development
Table 67. Gilead Sciences Company Details
Table 68. Gilead Sciences Business Overview
Table 69. Gilead Sciences Scleroderma Drug Product
Table 70. Gilead Sciences Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 71. Gilead Sciences Recent Development
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Scleroderma Drug Product
Table 75. Pfizer Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 76. Pfizer Recent Development
Table 77. Sanofi Company Details
Table 78. Sanofi Business Overview
Table 79. Sanofi Scleroderma Drug Product
Table 80. Sanofi Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 81. Sanofi Recent Development
Table 82. Boehringer Ingelheim Company Details
Table 83. Boehringer Ingelheim Business Overview
Table 84. Boehringer Ingelheim Scleroderma Drug Product
Table 85. Boehringer Ingelheim Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 86. Boehringer Ingelheim Recent Development
Table 87. Corbus Pharmaceuticals Company Details
Table 88. Corbus Pharmaceuticals Business Overview
Table 89. Corbus Pharmaceuticals Scleroderma Drug Product
Table 90. Corbus Pharmaceuticals Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 91. Corbus Pharmaceuticals Recent Development
Table 92. Actelion Pharmaceuticals Company Details
Table 93. Actelion Pharmaceuticals Business Overview
Table 94. Actelion Pharmaceuticals Scleroderma Drug Product
Table 95. Actelion Pharmaceuticals Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 96. Actelion Pharmaceuticals Recent Development
Table 97. Bayer Company Details
Table 98. Bayer Business Overview
Table 99. Bayer Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 100. Bayer Recent Development
Table 101. Cytori Therapeutics Company Details
Table 102. Cytori Therapeutics Business Overview
Table 103. Cytori Therapeutics Scleroderma Drug Product
Table 104. Cytori Therapeutics Revenue in Scleroderma Drug Business (2016-2021) & (US$ Million)
Table 105. Cytori Therapeutics Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Scleroderma Drug Market Share by Type: 2020 VS 2027
Figure 2. Anti-inflammatory Agents Features
Figure 3. Immunosuppressive Agents Features
Figure 4. Anti-fibrotic Agents Features
Figure 5. Global Scleroderma Drug Market Share by Application: 2020 VS 2027
Figure 6. Hospital Pharmacy Case Studies
Figure 7. Retail Pharmacy Case Studies
Figure 8. Online Pharmacy Case Studies
Figure 9. Scleroderma Drug Report Years Considered
Figure 10. Global Scleroderma Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Scleroderma Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Scleroderma Drug Market Share by Regions: 2020 VS 2027
Figure 13. Global Scleroderma Drug Market Share by Regions (2022-2027)
Figure 14. Global Scleroderma Drug Market Share by Players in 2020
Figure 15. Global Top Scleroderma Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Drug as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Scleroderma Drug Revenue in 2020
Figure 17. Global Scleroderma Drug Revenue Market Share by Type (2016-2021)
Figure 18. Global Scleroderma Drug Revenue Market Share by Type (2022-2027)
Figure 19. North America Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Scleroderma Drug Market Share by Type (2016-2027)
Figure 21. North America Scleroderma Drug Market Share by Application (2016-2027)
Figure 22. North America Scleroderma Drug Market Share by Country (2016-2027)
Figure 23. United States Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Scleroderma Drug Market Share by Type (2016-2027)
Figure 27. Europe Scleroderma Drug Market Share by Application (2016-2027)
Figure 28. Europe Scleroderma Drug Market Share by Country (2016-2027)
Figure 29. Germany Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Scleroderma Drug Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Scleroderma Drug Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Scleroderma Drug Market Share by Region (2016-2027)
Figure 39. China Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Scleroderma Drug Market Share by Type (2016-2027)
Figure 47. Latin America Scleroderma Drug Market Share by Application (2016-2027)
Figure 48. Latin America Scleroderma Drug Market Share by Country (2016-2027)
Figure 49. Mexico Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Scleroderma Drug Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Scleroderma Drug Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Scleroderma Drug Market Share by Country (2016-2027)
Figure 55. Turkey Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Scleroderma Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Cumberland Pharmaceuticals Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 59. Gilead Sciences Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 61. Sanofi Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 62. Boehringer Ingelheim Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 63. Corbus Pharmaceuticals Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 64. Actelion Pharmaceuticals Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 65. Bayer Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 66. Cytori Therapeutics Revenue Growth Rate in Scleroderma Drug Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed


【掲載企業】

Cumberland Pharmaceuticals、Gilead Sciences、Pfizer、Sanofi、Boehringer Ingelheim、Corbus Pharmaceuticals、Actelion Pharmaceuticals、Bayer、Cytori Therapeutics

★調査レポート[世界の強皮症治療薬市場規模・現状・予測2021-2027] (コード:QY21APR5135)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の強皮症治療薬市場規模・現状・予測2021-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆